

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Health and Happiness (H&H) International Holdings Limited

健合 (H&H) 國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1112)

**RESIGNATION OF NON-EXECUTIVE DIRECTORS
AND
APPOINTMENT OF EXECUTIVE DIRECTORS**

SUMMARY

The board of directors of the Company announces that both Mr. Chen Fufang and Mr. Wu Xiong have resigned as non-executive Directors with effect from 26 March 2018.

The board of directors of the Company further announces that Mrs. Laetitia Garnier and Mr. Wang Yidong have been appointed as executive Directors with effect from 26 March 2018.

RESIGNATION OF NON-EXECUTIVE DIRECTORS

The board of directors (the “**Board**” or the “**Directors**” and each a “**Director**”) of Health and Happiness (H&H) International Holdings Limited (the “**Company**”, together with its subsidiaries (the “**Group**”)) announces that Mr. Chen Fufang and Mr. Wu Xiong have tendered their resignation as non-executive Directors with effect from 26 March 2018 due to their wishes to devote more time to their personal engagements. Both Mr. Chen Fufang and Mr. Wu Xiong confirm that they have no disagreements with the Board and there are no matters with respect to their resignation that need to be brought to the attention of The Stock Exchange of Hong Kong Limited (the “**Hong Kong Stock Exchange**”) and the shareholders of the Company.

APPOINTMENT OF EXECUTIVE DIRECTORS

The board of Directors announces that Mrs. Laetitia Garnier and Mr. Wang Yidong have been appointed as executive Directors with effect from 26 March 2018.

The biographic details of Mrs. Laetitia Garnier and Mr. Wang Yidong are set out below:

Mrs. Laetitia Garnier (安玉婷), aged 37, joined the Group in July 2010. She is currently the Chief Strategy Officer of the Group. Before that, she was the General Manager of the Group Strategy and International Business. She is mainly responsible for Group strategy, acquisitions and investments, Group integration and management of Group international operations and business development. Since October 2016, Mrs. Laetitia Garnier has also assumed the role of Managing Director of Swisse China. From December 2003 to August 2010, she worked for the French Trade Commission in South China and was mainly responsible for providing lobbying and support to French companies partnering, exporting and investing in China, especially in the field of consumer goods and health sectors. Prior to that, she also has interned with the United States Senate in Washington D.C. from January to June 2001, the Banque Populaire Group in Paris from July to September 2001 and the LVMH Group in Paris from September 2002 to March 2003. In July 2003, she obtained a master's degree in business administration and corporate strategy from the Institute of Political Studies in Paris.

Mrs. Laetitia Garnier is also a director of various subsidiaries of the Company, including Biostime Healthy Australia Pty Ltd, Swisse Wellness Group Pty Ltd and Swisse China Limited etc.

Save as disclosed above, Mrs. Laetitia Garnier has not held any other directorships in other listed public companies in the past three years.

Mrs. Laetitia Garnier will enter into a service contract with the Company for her position as an executive Director of the Company for an initial term of three years commencing from 26 March 2018 which may be terminated by either party furnishing written notice of not less than three months and in any event subject to rotation, retirement and re-election at an annual general meeting pursuant to the articles of association of the Company. The service contract is automatically renewable upon expiration. The director fee payable to Mrs. Laetitia Garnier is RMB200,000 per annum.

Save as disclosed above, the Board is not aware of any other matters in relation to the appointment of Mrs. Laetitia Garnier that need to be brought to the attention of the shareholders of the Company or any information that needs to be disclosed pursuant to the requirement of the Rules 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities on the Stock Exchange (the "**Listing Rules**").

Mr. Wang Yidong (王亦東), aged 44, joined the Group in May 2016. Mr. Wang Yidong is the Chief Financial Officer of the Group and is in charge of the overall financial management, accounting and investor relations affairs of the Group. He has nearly 20 years of experience in financial management, accounting and corporate finance. Prior to joining the Group, Mr. Wang Yidong was the Corporate Vice President and Asia Pacific Chief Financial Officer of Henkel AG & Co. KGaA, a German consumer goods giant (“Henkel”), responsible for Henkel’s financial management, business and operation controlling as well as M&A-related tasks in 14 countries of Asia Pacific. Before that, he worked at Henkel’s headquarters in Germany as Global Director of Business Development and M&A for the Adhesive business unit, and also worked as Henkel’s Greater China Chief Financial Officer and Asia Pacific Treasurer in preceding years. Mr. Wang Yidong had also taken various management and banking roles with LG.Philips, JPMorgan Investment Bank and China’s Ministry of Commerce in Hong Kong, New York and Beijing. Mr. Wang Yidong holds a Master of Business Administration degree from New York University Stern School of Business and a Bachelor of Arts degree from China Foreign Affairs University. He is a member of the American Institute of Certified Public Accountants (the “AICPA”) and a member of the Association of Chartered Certified Accountants (the “ACCA”). He is also a member of ACCA China Expert Forum.

Mr. Wang Yidong is also a director of the Company’s subsidiary Adimil (Changsha) Nutrition Products Limited and associated company Hangzhou Coamie Personal Care Products Co., Ltd.

Save as disclosed above, Mr. Wang Yidong has not held any other directorships in other listed public companies in the past three years.

Mr. Wang Yidong will enter into a service contract with the Company for his position as an executive Director of the Company for an initial term of three years commencing from 26 March 2018 which may be terminated by either party furnishing written notice of not less than three months and in any event subject to rotation, retirement and re-election at annual general meeting pursuant to the articles of association of the Company. The service contract is automatically renewable upon expiration. The director fee payable to Mr. Wang Yidong is RMB200,000 per annum.

Save as disclosed above, the Board is not aware of any other matters in relation to the appointment of Mr. Wang Yidong that need to be brought to the attention of the shareholders of the Company or any information that needs to be disclosed pursuant to the requirement of the Rules 13.51(2)(h) to (v) of Listing Rules.

The Board is pleased to announce that Mrs. Laetitia Garnier and Mr. Wang Yidong have been appointed as the executive Directors with effect from 26 March 2018.

The Board would like to take this opportunity to express its sincere gratitude to Mr. Chen Fufang and Mr. Wu Xiong for their contributions to the Group during their tenure of services and to extend its warm welcome to Mrs. Laetitia Garnier and Mr. Wang Yidong on their new appointments.

By order of the Board
Health and Happiness (H&H) International Holdings Limited
Luo Fei
Chairman

Hong Kong, 25 March 2018

As at the date of this announcement, the executive Director of the Company is Mr. Luo Fei; the non-executive Directors of the Company are Dr. Zhang Wenhui, Mr. Wu Xiong, Mr. Luo Yun and Mr. Chen Fufang; and the independent non-executive Directors of the Company are Dr. Ngai Wai Fung, Mr. Tan Wee Seng and Professor Xiao Baichun.